Protocol Page


	Study ID (Protocol Number)
	CA182-037


	STUDY LOCATIONS*
	Montefiore Medical Center Bronx, NY 10467 Recruiting	Richard Finn, M.D. Los Angeles, CA 90095 Recruiting
	Rhode Island Hospital Providence, RI 02903 Recruiting	Seattle Cancer Care Alliance Seattle, WA 98109 Recruiting
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC
	STUDY OVERVIEW
	The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.